• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

19种同构多组分阿普斯特形式的独特且系统数据集的结构-性质关系

Structure-property relations of a unique and systematic dataset of 19 isostructural multicomponent apremilast forms.

作者信息

Jirát Jan, Babor Martin, Ridvan Luděk, Skořepová Eliška, Dušek Michal, Šoóš Miroslav

机构信息

Department of Chemical Engineering, University of Chemistry and Technology, Technická 3, Prague 6 16628, Czech Republic.

Zentiva, k.s, U kabelovny 130, Prague 10 10237, Czech Republic.

出版信息

IUCrJ. 2022 Jun 15;9(Pt 4):508-515. doi: 10.1107/S2052252522005577. eCollection 2022 Jul 1.

DOI:10.1107/S2052252522005577
PMID:35844478
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9252161/
Abstract

The structure-property relations are examined for apremilast cocrystals and solvates in this work. A unique and large dataset of multicomponent crystal forms is presented including 7 cocrystals and 12 solvates. In total, 15 of the presented multicomponent forms and their crystal structures are published here for the first time. This dataset is unique owing to the extreme crystal packing similarity of all 19 crystal forms. This fact makes the evaluation of structure-property relations significantly easier and more precise since the differences in the crystal lattice arrangement are close to negligible. Properties of the guest molecules used here can be directly correlated with the macroscopic properties of the corresponding multicomponent forms. Interestingly, a considerable correlation was found between the intrinsic dissolution rate of the multicomponent forms and their solubility, as well as the solubility of their guest molecules in the dissolution medium. The latter is of particular interest as it can aid in the design of multicomponent forms with tuned properties.

摘要

在本工作中,对阿普斯特共晶体和溶剂化物的结构-性质关系进行了研究。展示了一个独特且庞大的多组分晶体形式数据集,包括7种共晶体和12种溶剂化物。总共15种所展示的多组分形式及其晶体结构在此首次发表。由于所有19种晶体形式的晶体堆积极为相似,该数据集独具特色。这一事实使得结构-性质关系的评估显著更容易且更精确,因为晶格排列的差异几乎可以忽略不计。此处使用的客体分子的性质可直接与相应多组分形式的宏观性质相关联。有趣的是,发现多组分形式的固有溶解速率与其溶解度以及客体分子在溶解介质中的溶解度之间存在显著相关性。后者尤其令人感兴趣,因为它有助于设计具有调控性质的多组分形式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfb/9252161/1c0293dd6eb2/m-09-00508-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfb/9252161/ec4c1ef7217c/m-09-00508-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfb/9252161/0b4d21d9b44f/m-09-00508-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfb/9252161/8e293b779dce/m-09-00508-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfb/9252161/a34f485a8bfe/m-09-00508-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfb/9252161/1c0293dd6eb2/m-09-00508-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfb/9252161/ec4c1ef7217c/m-09-00508-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfb/9252161/0b4d21d9b44f/m-09-00508-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfb/9252161/8e293b779dce/m-09-00508-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfb/9252161/a34f485a8bfe/m-09-00508-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfb/9252161/1c0293dd6eb2/m-09-00508-fig5.jpg

相似文献

1
Structure-property relations of a unique and systematic dataset of 19 isostructural multicomponent apremilast forms.19种同构多组分阿普斯特形式的独特且系统数据集的结构-性质关系
IUCrJ. 2022 Jun 15;9(Pt 4):508-515. doi: 10.1107/S2052252522005577. eCollection 2022 Jul 1.
2
Understanding the formation of apremilast cocrystals.了解阿普斯特共晶体的形成。
Acta Crystallogr B Struct Sci Cryst Eng Mater. 2019 Oct 1;75(Pt 5):803-814. doi: 10.1107/S205252061900917X. Epub 2019 Sep 7.
3
Improving the dissolution behaviors and bioavailability of abiraterone acetate via multicomponent crystal forms.通过多晶型物改善醋酸阿比特龙的溶解行为和生物利用度。
Int J Pharm. 2022 Feb 25;614:121460. doi: 10.1016/j.ijpharm.2022.121460. Epub 2022 Jan 10.
4
Isostructural cocrystals of metaxalone with improved dissolution characteristics.具有改善溶解特性的美索巴莫等结构共晶体。
RSC Adv. 2021 Sep 15;11(49):30689-30700. doi: 10.1039/d1ra05959a. eCollection 2021 Sep 14.
5
Strategy and Methodology in the Synthesis of Multicomponent Molecular Solids: The Quest for Higher Cocrystals.多组分分子固体的合成策略与方法学:追求更高共晶的探索。
Acc Chem Res. 2019 Aug 20;52(8):2210-2220. doi: 10.1021/acs.accounts.9b00211. Epub 2019 Jul 18.
6
Pharmaceutical cocrystals: a novel approach for oral bioavailability enhancement of drugs.药物共晶:提高药物口服生物利用度的新方法。
Crit Rev Ther Drug Carrier Syst. 2012;29(3):183-218. doi: 10.1615/critrevtherdrugcarriersyst.v29.i3.10.
7
Multicomponent solid forms of the uric acid reabsorption inhibitor lesinurad and cocrystal polymorphs with urea: DFT simulation and solubility study.尿酸重吸收抑制剂雷西纳德的多组分固体形式及与尿素的共晶多晶型物:密度泛函理论模拟与溶解度研究
Acta Crystallogr C Struct Chem. 2019 Aug 1;75(Pt 8):1102-1117. doi: 10.1107/S2053229619008829. Epub 2019 Jul 9.
8
Comparison of the crystal structures and physicochemical properties of novel resveratrol cocrystals.新型白藜芦醇共晶体的晶体结构与理化性质比较
Acta Crystallogr B Struct Sci Cryst Eng Mater. 2019 Dec 1;75(Pt 6):1186-1196. doi: 10.1107/S2052520619013477. Epub 2019 Nov 23.
9
Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development.药用共晶体:监管与战略层面、设计与开发
Adv Pharm Bull. 2016 Dec;6(4):479-494. doi: 10.15171/apb.2016.062. Epub 2016 Dec 22.
10
Formation of ibrutinib solvates: so similar, yet so different.伊布替尼溶剂化物的形成:如此相似,却又如此不同。
IUCrJ. 2023 Mar 1;10(Pt 2):210-219. doi: 10.1107/S2052252523001197.

引用本文的文献

1
Apremilast Cocrystals with Phenolic Coformers.阿普斯特与酚类共形成物的共晶体。
Molecules. 2024 Dec 23;29(24):6060. doi: 10.3390/molecules29246060.

本文引用的文献

1
Understanding the formation of apremilast cocrystals.了解阿普斯特共晶体的形成。
Acta Crystallogr B Struct Sci Cryst Eng Mater. 2019 Oct 1;75(Pt 5):803-814. doi: 10.1107/S205252061900917X. Epub 2019 Sep 7.
2
Complex methodology for rational design of Apremilast-benzoic acid co-crystallization process.阿普司特-苯甲酸共结晶工艺的合理设计的复杂方法学。
Int J Pharm. 2019 Oct 30;570:118639. doi: 10.1016/j.ijpharm.2019.118639. Epub 2019 Aug 26.
3
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.阿普司特治疗银屑病及其他疾病:对一种小分子药物寄予厚望
Indian Dermatol Online J. 2019 Jan-Feb;10(1):1-12. doi: 10.4103/idoj.IDOJ_437_18.
4
The preparation, characterization, structure and dissolution analysis of apremilast solvatomorphs.阿普斯特溶剂化物的制备、表征、结构及溶出度分析
Acta Crystallogr C Struct Chem. 2017 Apr 1;73(Pt 4):305-313. doi: 10.1107/S2053229617002984. Epub 2017 Mar 6.
5
Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis.阿普米司特(欧泰乐):一种用于成人银屑病和银屑病关节炎的新型口服治疗药物。
P T. 2015 Aug;40(8):495-500.
6
Acemetacin cocrystals and salts: structure solution from powder X-ray data and form selection of the piperazine salt.醋氨己酸钙共晶和盐:粉末 X 射线数据的结构解析及哌嗪盐的形式选择。
IUCrJ. 2014 Feb 28;1(Pt 2):136-50. doi: 10.1107/S2052252514004229. eCollection 2014 Mar 1.
7
Loss of orally administered drugs in GI tract.胃肠道中口服药物的损失。
Saudi Pharm J. 2012 Oct;20(4):331-44. doi: 10.1016/j.jsps.2012.03.005. Epub 2012 Apr 20.
8
Pharmaceutical cocrystals: an overview.药物共晶:概述。
Int J Pharm. 2011 Oct 31;419(1-2):1-11. doi: 10.1016/j.ijpharm.2011.07.037. Epub 2011 Aug 2.
9
Nanonization strategies for poorly water-soluble drugs.纳米化策略用于改善水溶性差的药物。
Drug Discov Today. 2011 Apr;16(7-8):354-60. doi: 10.1016/j.drudis.2010.02.009. Epub 2010 Mar 3.
10
Pharmaceutical Cocrystals and Their Physicochemical Properties.药用共晶体及其物理化学性质。
Cryst Growth Des. 2009 Jun 3;9(6):2950-2967. doi: 10.1021/cg900129f. Epub 2009 Apr 20.